Foghorn Therapeutics (FHTX) Profit After Tax (2019 - 2026)

Foghorn Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$19.9 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 5.66% year-over-year to -$19.9 million; the TTM figure through Mar 2026 stood at -$75.4 million (up 6.28% YoY), while the FY2025 annual figure was -$74.3 million, up 14.22% from the prior year.
• Profit After Tax was -$19.9 million for Q1 2026 at Foghorn Therapeutics, up from -$21.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$14.3 million in Q3 2023 to a low of -$30.5 million in Q1 2023.
• Historically, Profit After Tax has averaged -$22.8 million across 5 years, with a median of -$23.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax surged 44.33% in 2023, then sank 33.3% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$28.9 million in 2022, then rose by 16.53% to -$24.1 million in 2023, then rose by 19.24% to -$19.5 million in 2024, then fell by 11.29% to -$21.7 million in 2025, then gained by 8.22% to -$19.9 million in 2026.
• The last three Profit After Tax figures came in at -$19.9 million (Q1 2026), -$21.7 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.